

**Supplementary Table 3.** Resource utilization for patients with MDD receiving open-label adjunctive brexpiprazole 0.5–3 mg/day

	Safety population (n=2,938)		
	Baseline*	Week 26 <sup>†</sup>	Week 52 <sup>‡</sup>
Number of hospitalizations for the treatment of emotions, nerves, or mental health	0.0 (n=2,919)	0.0 (n=996)	0.0 (n=765)
Number of days in hospital for the treatment of emotions, nerves, or mental health	2.2 (n=400)	0.3 (n=117)	0.1 (n=49)
Number of visits to:	(n=2,919)	(n=2,063)	(n=769)
Primary care doctor	1.9	1.6	1.4
Psychiatrist	0.6	0.5	0.6
Counsellor, psychologist, or other mental health professional	1.2	0.9	0.6
Other physician	1.0	0.7	0.7
Emergency room or urgent care facility for emotions, nerves, or mental health	0.0	0.0	0.0
Emergency room or urgent care facility for other reason	0.3	0.2	0.1

MDD, major depressive disorder.

\*Data collected for the past 12 months (hospitalizations) or past 3 months (medical care visits) and presented as annual use (average use per 365.25 person days).

<sup>†</sup>Data collected for the period from baseline to Week 26 and presented as annual use (average use per 365.25 person days).

<sup>‡</sup>Data collected for the period from baseline to Week 52 and presented as annual use (average use per 365.25 person days).